ScinoPharm Taiwan Ltd
TWSE:1789
ScinoPharm Taiwan Ltd
Operating Income
ScinoPharm Taiwan Ltd
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Operating Income
NT$314.5m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-14%
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Operating Income
NT$929.6m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
Formosa Laboratories Inc
TWSE:4746
|
Operating Income
NT$675m
|
CAGR 3-Years
189%
|
CAGR 5-Years
62%
|
CAGR 10-Years
N/A
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Operating Income
NT$160.3m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-2%
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Operating Income
NT$4.4B
|
CAGR 3-Years
30%
|
CAGR 5-Years
40%
|
CAGR 10-Years
47%
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Operating Income
NT$1.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
28%
|
CAGR 10-Years
18%
|
See Also
What is ScinoPharm Taiwan Ltd's Operating Income?
Operating Income
314.5m
TWD
Based on the financial report for Dec 31, 2023, ScinoPharm Taiwan Ltd's Operating Income amounts to 314.5m TWD.
What is ScinoPharm Taiwan Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-14%
Over the last year, the Operating Income growth was -22%. The average annual Operating Income growth rates for ScinoPharm Taiwan Ltd have been -6% over the past three years , -11% over the past five years , and -14% over the past ten years .